viimane versioon :
19/11/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Hydrocortisone
keemiline struktuur
Viited : Hydrocortisone
tüüp
avaldamine
909
ajaleht
Chong G, Decarie D, Ensom M.H.H.
Stability of hydrocortisone in extemporaneously compounded suspensions.
J Informed Pharmacother 2003 ; 13: 100-110.
2538
ajaleht
Fawcett JP, Boulton DW, Jiang R, Woods DJ.
Stability of hydrocortisone oral suspensions prepared from tablets and powder.
Ann Pharmacotherapy 1995 ;29:987-990.
2835
ajaleht
Das Gupta V.
Chemical Stability of Hydrocortisone in an Oral Liquid Dosage Form without Suspending Agents
Int J Pharm Compound 2007 ; 11, 3: 259-261.
3755
ajaleht
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R.
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Int J Pharm Compound 2014 ; 18, 5: 427-431.
3810
ajaleht
Geiger C M, Sorenson B, Whaley P.
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF.
Int J Pharm Compound 2015 ; 19, 5 : 420-427.
3811
ajaleht
Nahata Milap C.
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures.
Int J Pharm Compound 2015 ; 19, 5 : 428-431.
4063
ajaleht
Manchanda A, Laracy M, Savji T, Bogner R.
Stability of an Alcohol-free, Dye-free Hydrocortisone (2mg/mL) Compounded Oral Suspension.
Int J Pharm Compound 2018 ;22,1:66-75
4198
ajaleht
Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4530
ajaleht
Pramar Y, Mandal T, Bostanian L, Kader C, Morris T, Graves R.
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt.
Int J Pharm Compound 2021 ;25,5:431-439
Mentions Légales
